Biophytis provides an update on the rollout of its joint venture in Hong Kong (see details in the “About” section below) and shares its short- and medium-term outlook. Landmark milestones achieved and imminent progress The creation of the joint venture Biophytis Biopharmaceutical Holding LTD, announced on June 2, 2026, paves the way for the full…
Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research Next-generation drug candidates against sarcopenia Next generation drug candidates for dry age-related macular degeneration (AMD) Paris (France), Cambridge…
Biophytis announces the signing of a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding Ltd, designed to accelerate the development and commercialization of BIO101 in sarcopenia in Asian markets.
BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong Kong Injection of US$20 million by the consortium of Asian investors Start of clinical operations in early 2026 A landmark Memorandum of Understanding (MoU) has…
Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing its OBA Phase 2 trial of BIO101 in muscle wasting associated with obesity. The Company via its subsidiary in Brazil has secured funding support from EMBRAPII (Empresa Brasileira de Pesquisa e…
Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artificial intelligence solutions for life sciences. The collaboration aims to accelerate the discovery and development…
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China Biophytis today announces the signing of a co-development agreement with AskHelpU, the largest patient association in China for those affected by amyotrophic lateral sclerosis (ALS). Fullscreen Mode
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 Biophytis announces that it has entered exclusive negotiations with a leading Chinese pharmaceutical company. The purpose of these discussions is to finalize a licensing agreement to co-develop and commercialize BIO101 (20-Hydroxyecdysone) in China for its most promising and advanced indications: viral respiratory infections,…
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia Biophytis announces the deployment of its partnership strategy in Asia. To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for China and Southeast Asia. These…
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Seqens, an integrated global player in solutions and ingredients for the pharmaceutical and speciality markets, offering a broad portfolio of active ingredients, pharmaceutical intermediates and speciality products, has produced the first GMP-compliant batch of BIO101 (20-hydroxyecdysone) at its plant in…
Biophytis and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure Biophytis announces the signing of a new partnership with the University of Liège to carry out a range of preclinical research projects, particularly in the treatment of respiratory failure caused by the flu virus Influenza. Under…
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) Biophytis and Skyepharma, a French pharmaceutical company specializing in the formulation, development and production of pharmaceutical products, announce the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19, with a view to…
Biophytis and SEQENS sign a partnership to produce Sarconeos Biophytis, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases and SEQENS, integrated global player in solutions and ingredients for the pharmaceutical and specialty…
Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-19 Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for…
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study Fullscreen Mode
